Cargando…
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for cancer patients with BRCA mutations. PARP inhibitors...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369301/ https://www.ncbi.nlm.nih.gov/pubmed/35955544 http://dx.doi.org/10.3390/ijms23158412 |